Enliven Therapeutics heads into its May 11 earnings release carrying the fingerprints of a short-side exodus — but options traders remain more defensively positioned than usual.
Short sellers have been quietly exiting. Short Interest % of Free Float fell from roughly 13% in early April to 9.4% today — a drop of more than 27% over the past month. The retreat is decisive. It accelerated sharply after April 9–10, when short shares outstanding peaked near 7.7 million, and has continued steadily since. Borrowing costs are now trivial at 0.41% APR, down nearly a quarter over the same period, and borrow availability remains loose — less than 13% of available shares are currently lent out, down dramatically from the 52-week high of 70.7%. Bears who wanted to press the short side have been unwinding, not adding.
Options tell a more cautious story. The put/call ratio is running at 1.92 — meaningfully above its 20-day average of 1.56. That level is not extreme by historical standards (the 52-week high hit 22.2 at its peak), but it does confirm that options traders are biased toward protection rather than upside participation heading into the print. The stock itself is down around 2% on the week and off roughly 16% from its mid-April high near $48, even as it has recovered about 3.5% over the past month from its April lows.
The bull-bear debate centres on pipeline execution. Bulls point to EO-1022, a HER3-targeting antibody-drug conjugate, as the core long-term value driver, with HC Wainwright raising its target to $56 and Mizuho lifting to $45, both in late March. Both firms maintained constructive ratings. The consensus target of $51.29 sits roughly 27% above the current price. Bears counter with the discontinued EO-3021 program — a Claudin 18.2-targeting ADC dropped after weak Phase 1 efficacy data — arguing that the pipeline is now narrower and the company's ability to convert science into approvable drugs is unproven. Valuation is no anchor: the P/E is deeply negative (Enliven is pre-revenue), so the print is a clinical and operational read, not a financial one.
EPS momentum factors are a quiet bright spot. The 30-day and 90-day EPS momentum scores rank in the 73rd and 89th percentiles of the universe respectively, suggesting estimate revisions have been running in the right direction heading into this release. Past earnings reactions have been mixed but modest — the most recent Q4 report on March 13 saw the stock fall 4.9% on the day before recovering flat over five sessions. May 11 is therefore less a test of the income statement and more a test of whether management's updated clinical narrative on EO-1022 can justify the Street's target prices — and bring short sellers all the way back to the sidelines.
See the live data behind this article on ORTEX.
Open ELVN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
